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Introduction
Epstein-Barr virus (EBV) has been implicated in the development of a
wide  range  of  cancers  such  as  nasopharyngeal  carcinoma  (NPC),
Hodgkin’s disease, and Burkitt’s lymphoma since its discovery as the first
human tumor virus [1]. EBV encodes multiple viral proteins, and the ex-
pression patterns of those proteins in human malignancies are variable.
Some of viral products such as latent membrane protein (LMP)-1 and
EBV nuclear antigen 2 have been suggested to be important in the onco-
genic process of many EBV-associated cancers.
EBV is found in approximately 10% of gastric cancers (GCs) [2], and
is proposed to have a critical role in EBV-associated GCs since the virus
is present all cancer cells and carcinoma is formed by the proliferation of
a single EBV infected cell [3]. However, the specific genes from EBV
genome contributing to the carcinogenesis of GCs still remain unknown.
The latency pattern in EBV-carrying GCs is distinct from the other EBV-
associated malignancies by the absence of LMP 1, LMP2B [4] and the
Cancer Res Treat. 2011;43(4):250-254
pISSN 1598-2998, eISSN 2005-9256
http://dx.doi.org/10.4143/crt.2011.43.4.250
Bo-Gun Jang,MD1
Eun Ji Jung,MS2
Woo Ho Kim, MD, PhD1,2
1Department of Pathology, 2Cancer Research
Institute, Seoul National University College
of Medicine, Seoul, Korea
Correspondence: Woo Ho Kim, MD, PhD
Department of Pathology, Seoul National 
University College of Medicine, Yeongeon-dong,
Jongno-gu, Seoul 110-799, Korea
Tel: 82-2-740-8269
Fax: 82-2-765-5600
E-mail: woohokim@snu.ac.kr
Received  July 29, 2011
Accepted  September 28, 2011
Purpose
About 10% of all gastric cancers (GCs) are Epstein-Barr virus (EBV)-associated. However, the
oncogene of EBV in gastric carcinogenesis has not yet been established. In the present study,
we investigated the virus-derived transcripts in the EBV-infected GC cell line to explore the viral
oncogene of EBV-positive GCs.
Materials and Methods
We used the SNU719 cell line, a naturally derived EBV-infected GC cell line. The individual ex-
pressed sequence tags from the cDNA libraries of SNU719 were searched against the mRNA
subset extracted from the GenBank data base. Sequence reaction was carried out for the EBV-
associated clones. Reverse transcription-polymerase chain reaction was performed after cells
were partitioned into nuclear and cytoplasmic fractions.
Results
Using bioinformatic tools, we selected 13 EBV-associated clones from cDNA libraries of SNU719.
By sequencing analysis, we revealed that they were all associated with RPMS1, one of the BamHI-
A rightward transcripts (BART) of EBV. Some BART cDNAs such as RPMS1 and A73 are known
to be translated into proteinin vitro, and have been shown to have some biochemical functions
relevant to tumorigenesis. But, presently, the BART transcripts were expressed only in the nucleus
and not in the cytoplasm, arguing against their role as messenger RNAs. Some other BART tran-
scripts expressed in GCs (BARF0, CST, vIL, BARF1, BLLF1, and BcLF1) were also extensively de-
tected in the nucleus.
Conclusion
BART transcripts are the predominant viral transcripts expressed in EBV-associated GCs, and
they are located only in the nucleus. Therefore, it seems less likely that BART transcripts produce
functional proteins to play a role in carcinogenesis of EBV-associated GCs.
Key words
Stomach neoplasms, Epstein-Barr virus, 
Oncogenes, RPMS protein
Original Article Open Access
Expression of BamHI-A Rightward Transcripts in 
Epstein-Barr Virus-Associated Gastric Cancers
Copyright ⓒ2011 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0/)whichpermitsunrestrictednon-commercialuse,distribution, andreproductioninanymedium,providedtheoriginalworkisproperlycited.
250Bo-Gun Jang, BARTs in EBV-Associated Gastric Cancers
VOLUME 43  NUMBER 4  DECEMBER  2011   251
expression of the BARF1 [5]. Some EBV genes are suggested to have an
oncogenic role in EBV-carrying GCs. For example, BARF1, which is ex-
clusively expressed in EBV-associated GCs, has oncogenic properties in
many cell types such as monkey kidney epithelial cell line [6] and human
B lymphocytes [7], and human epithelial cell line HBE [8]. In addition,
cyclin D1 induced in BARF1-transfected epithelial cells was overex-
pressed in EBV-associated GCs, indicating an interaction of viral BARF1
and cyclin D1 [9]. However, BARF1 transcripts have never been shown
to produce protein in EBV-positive GCs. Thus, it requires further study
to confirm the oncogenic role of BARF1 in EBV-associated GCs. 
As EBV-infected GC cells show the specific latency pattern of viral
gene expression and usually do not express the major oncogenic LMP1,
we tried to identify the specific transcripts implicated in the carcinogenesis
of EBV-positive GCs from EBV-infected gastric cancer cell lines. In this
study, we searched for EBV-associated clones in cDNA libraries estab-
lished from the EBV-infected GC cell line, SNU719, to find novel viral
oncogenes in GCs, and investigated their expression in SNU719 cells.
M ater ials  and  M eth od s
1. Cell line
The SNU719 cell line was used. It is a naturally derived EBV-infected
cell line, which was established from a 53-year-old male patient with pri-
mary stomach cancer tissue in July 1991 [10]. It was obtained from the
Korean Cell Line Bank (Seoul, Korea) and was cultured in RPMI-1640
supplemented with 10% heat-inactivated FBS (Hyclone, Logan, UT) at
37ﾰC in a humidified CO2incubator.
2. Bioinformatic analysis of EBV-associated expressed sequence tags
(ESTs)
Two cDNA libraries derived from SNU719 are available in the Na-
tional Center for Biotechnology Information (NCBI) UniGene database
(http://www.ncbi.nlm.nih.gov/unigene).  The  individual  ESTs  were
searched against the mRNA subset extracted from the GenBank data base.
The selected clones were obtained from 21C frontier Gene Bank (Dae-
jeon, Korea). Plasmid DNAs were extracted and sequencing reactions
were performed using a BigDye Terminator Sequencing kit (Applied
Biosystems, Foster City, CA). After the unincorporated dye terminator
was removed from the sequencing reaction, the reaction products were
applied to genetic analyzers (Applied Biosystems).
3. Reverse transcriptase polymerase chain reaction (RT-PCR)
After cells were partitioned into nuclear and cytoplasmic fraction, RNA
was extracted by PARIS (Ambion, Austin, TX). Five hundred nanograms
of RNA were used to synthesize cDNA using a random hexamers. Re-
verse transcription was carried out with Superscript Reverse Transcriptase
(Invitrogen, Carlsbad, CA). PCR was performed with primers which were
used in the previous studies [11,12]. The PCR reaction mixture consisted
of 1ￗ PCR premix (Takara, Shiga, Japan), 5 pmol of each primer, and 1
ʼL of cDNA. PCR involved 25 cycles of 95ﾰC, 30 seconds; 50-60ﾰC, 30
seconds; 72ﾰC, 1 minute followed by 10 minutes at 72ﾰC to complete re-
action. This experiment was repeated three times.
R esults
1. Analysis of EBV-associated ESTs from the SNU719 cDNA library
ESTs are useful for the differential and quantitative analysis for the
evaluation of gene expression profiles in a given tissue. We found two
SNU719 cDNA libraries (S7SNU719 and S7SNU719S1) established
from SNU719, EBV-infected gastric cancer cell line in NCBI’s UniGene
database. The total number of ESTs from the two libraries was 4,701. The
individual EST was searched against the mRNA subset extracted from
the GenBank data base. We selected 13 clones that had a possibility of
being transcribed from the EBV genome by Blast analysis. After each
clone was linearized with EcoR I and Not I, it was electrophoresed in 1%
agarose gel (Fig. 1). We classified them into five groups based on size.
Sequencing the clone from each five groups revealed that three groups of
clones-1.2 kb, 1.6 kb, and 2.5 kb-were derived from EBV genome and
a)The clones of Group 1 have an EcoR I recognition site that generated two segments of 1.2 kb and 0.4 kb after digestion with EcoR I and Not I.
Table 1. Summary of clones according to size
Clone number Size of clone (kb)
Associated gene of 
Epstein-Barr virus
Group 1a) 1, 2, 4, 6, 10, 11, 13 1.6 RPMS1
Group 2 7, 8, 9 1.2 RPMS1
Group 3 12 12 RPMS1
Group 4 3 0.3 None
Group 5 51 Nonewere related with the RPMS1 transcript that spans the whole BamHI-A
rightward transcript (BART) region of EBV (Table 1). BART transcripts
are a group of various splicing variants transcribed from 138352 to 160531
on the wild-type EBV genome, and some open reading frames (ORFs)
in those BART cDNAs have been actively investigated such as RPMS1
and A73. Through BLAST sequence alignment, three groups of clones
were included in RPMS1 cDNA. Group 3 clone covered most of the ORF
of RPMS1, whereas Group 1 and 2 clones showed no overlap with any
ORFs of RPMS1 and A73 (Fig. 2).
2. Analysis of cytoplasmic and nuclear EBV transcripts from EBV-
infected gastric cancer cell lines
Some BARTs such as RPMS1 and A73 have ORFs, and they have
been shown to produce proteinsin vitrowith significant biologic functions
relevant to carcinogenesis. However, it has never been demonstrated in
naturally EBV infected cells. Since we identified the various BARTs in
EBV-associated GC, we decided to investigate whether or not they might
be acting as mRNAs. If gene transcripts act as mRNAs, they will be de-
tected in the cytoplasm. Therefore, we probed for BART RNAs of
SNU719 in the cytoplasm. After cells were partitioned into nuclear and
cytoplasmic fractions, RNA was extracted and RT-PCR was performed
with primers specific for the spliced exons 3B-5 and 5-7 of BART. BART
RNA was almost completely in the nucleus (Fig. 3A). Some latent and
lytic transcripts that are expressed in EBV-associated GCs were also de-
tected in the nucleus only (Fig. 3B). However, we were not able to confirm
the expression of BART transcripts by Northern blot analysis. Although
we did not detect any BART transcripts in the cytoplasm of SNU719 cells,
it is still possible that BART transcripts might have been translated into
protein that functioned in the development of GCs. This role would likely
have been in the early stage of tumorigenesis, but not in fully developed
cancer cells. We are planning to try RNA in situhybridization for paraffin
embedded tissues to further explore the cytosolic BART transcripts in
dysplastic cells triggered by EBV infection, which is expected to clarify
the existence of BARTs in many different stages of gastric epithelial cells
undergoing transformation.
Discussion
BART RNAs were originally identified by analysis of the cDNA li-
braries established from the NPC cell line [13]. Since then, they have been
demonstrated to be expressed in many EBV-associated malignancies in-
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Fig. 1. Electrophoresis of 13 clones after digestion with EcoR I and
Not I. Clones 1, 2, 4, 6, 10, 11 and 13 showed two fragments of 1.2
kb and 0.4 kb because of their EcoR I recognition sites.
1                   800            1,600             2,400            3,200              4,000
RPMSI cDNA (4 kb)
A73 cDNA (2.1 kb)
Group 1 (1.6 kb)
EcoR 
ORF
ORF
Group 2 (1.2 kb)
Group 3 (2.5 kb)
Fig. 2. Sequence alignment of three groups of clones to the RPMS1
cDNA. The BLAST sequence alignment program was used to com-
pare the sequence of the clones to RPMS1. The open reading frames
(ORFs) of RPMS1 and A73 are shown by boxed segments. 
Fig. 3. Analysis of Epstein-Barr virus (EBV) transcripts comparing
cytoplasmic and nuclear RNA from SNU719. (A) Reverse transcrip-
tase polymerase chain reaction (RT-PCR) for BamHI-A rightward
transcripts (BART) RNAs using primers spanning BART exons 3B-
5 or 5-7. (B) RT-PCR for the some latent and lytic EBV transcripts.
The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was
used as an internal control.
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cluding EBV-positive GCs. In this study, we identified some BART RNAs
in the EBV-positive GC cell line. It is notable that all EBV-related clones
that we found from the cDNA library of EBV-positive GC cell line turned
out to be related with BART, which suggests that BART RNAs are quite
possibly the predominant transcripts from EBV genome in EBV-infected
GCs. 
Among these clones, the largest one (2.5 kb) contained the ORF of
RPMS1 indicating that RPMS1 protein might be translated if that cDNA
acts as mRNA. In fact, RPMS1 already has been shown to produce a nu-
clear protein in vitro, which could be detected using specific antibodies
that recognize artificially expressed RPMS1 protein. These findings
strongly support the possibility that RPMS1 could act as mRNA in vivo.
However, we observed RPMS1 transcripts exclusively expressed in the
nucleus  of  EBV-positive  GC  cells  by  performing  RT-PCR  after
nuclear/cytoplasmic fractionation, which argues against them acting as
mRNAs. Furthermore, previous studies also failed to detect the endoge-
nous RPMS1 protein in NPC or Burkitt lymphoma cases with the specific
monoclonal antibodies that were verified to be able to detect the recom-
binant RPMS1 protein [11,14,15]. Thus, it still remains uncertain that
RPMS1 transcripts produce a detectable protein in natural EBV infec-
tions.
Despite the lack of evidence of its acting as mRNA, RPMS1 clearly
has some biologic functions that are quite relevant to tumorigenesis. Ar-
tificially expressed RPMS1 protein antagonizes the transcription activation
by Notch 1 or EBVA2 through its interaction with the CBF1-associated
corepressor complex [15], and enhances anchorage-independent growth
of 293 cells and produce tumors in nude mice [16]. A73, another BARTs-
derived potential protein, has been translated in vitro and was shown to
bind to the cellular RACK1 and regulate calcium influx, even though the
existence of endogenous A73 protein has never been demonstrated [11].
These biologic functions could fit well with a pathologic role of EBV in
EBV-related cancers. Therefore, the possibility still remains, and we can
speculate that RPMS1 might be transiently expressed in specific circum-
stances only and contribute to the development of cancer. For example,
RPMS1 might be translated into the protein under a certain precancerous
stage, but not fully-developed cancer cells. Thus, it could be meaningful
to try to investigate the presence of RPMS1 protein in non-cancer cells
that are only infected by EBV or cells that are show dysplastic changes
after EBV infection.
The abundant BART RNA transcripts have been implicated in carcino-
genesis by contributing to the production of miRNAs. Since the first dis-
covery of EBV miRNAs from the Burkitt’s lymphoma cells, over 20
miRNAs have been identified [17,18]. These miRNAs were shown to be
present in EBV-infected GC cell lines and the tumor tissues from patients
[19]. Some targets for miRNAs have been unraveled such as EBV DNA
polymerase [20], EBV LMP1 [21], and p53 up-regulated modulator of
apoptosis [22]. Interestingly, these miRNAs are derived mainly from the
introns prior to splicing of the BART primary transcripts, and their ex-
pression is largely predicted by the level of expression of the BART RNAs
[18]. Based on the close correlation of expression of BART transcripts
and BART miRNAs, it can be suggested that the primary goal of the tran-
scription of BART might be to promote the production of miRNAs, not
to produce the viral proteins. Alternatively, BART transcripts might have
dual functions, serving as oncogenic proteins in precancerous stage and
then supplying miRNAs to support cell survival or immune evasion in
established cancer cells. 
C onclusion
In this study, we showed that BART transcripts are the predominant
viral transcripts expressed in EBV-associated GCs. We also observed they
are located in the nucleus only, indicating that BART transcripts are less
likely to produce functional proteins than they are to play a role in car-
cinogenesis of EBV-associated GCs.
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